PNC Financial Services Group Inc. Buys 53,135 Shares of Gilead Sciences, Inc. $GILD

Posted by Francis Steltz on May 22nd, 2026

Gilead Sciences logo PNC Financial Services Group Inc. grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 12.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 474,105 shares of the biopharmaceutical company’s stock after acquiring an additional 53,135 shares during the period. PNC Financial Services Group Inc.’s holdings in Gilead Sciences were worth $58,192,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of GILD. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in shares of Gilead Sciences by 52.1% during the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after acquiring an additional 26,882 shares during the period. Cookson Peirce & Co. Inc. raised its holdings in shares of Gilead Sciences by 249.1% during the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after acquiring an additional 7,168 shares during the period. Sector Gamma AS raised its holdings in shares of Gilead Sciences by 15.9% during the third quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after acquiring an additional 20,239 shares during the period. iA Global Asset Management Inc. raised its holdings in shares of Gilead Sciences by 11.6% during the third quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after acquiring an additional 23,046 shares during the period. Finally, NewEdge Wealth LLC raised its holdings in shares of Gilead Sciences by 2.9% during the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after acquiring an additional 17,284 shares during the period. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Weiss Ratings upgraded shares of Gilead Sciences from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, May 11th. TD Cowen raised their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Truist Financial reaffirmed a “buy” rating and issued a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Get Our Latest Stock Analysis on Gilead Sciences

Gilead Sciences Stock Down 0.1%

Gilead Sciences stock opened at $130.50 on Friday. The company has a market cap of $162.02 billion, a P/E ratio of 17.78 and a beta of 0.31. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a fifty day simple moving average of $136.50 and a 200 day simple moving average of $133.64. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Maxim Group upgraded Gilead to Buy from Hold and raised its price target to $165, implying meaningful upside from current levels. Maxim Group upgrades Gilead Sciences (GILD)
Positive Sentiment: Gilead completed its acquisition of Tubulis GmbH, adding next-generation antibody-drug conjugate assets that strengthen its oncology pipeline and could expand future growth opportunities. Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Positive Sentiment: New ASCO and EHA 2026 data and upcoming presentations highlight continued momentum in Gilead and Kite’s oncology programs, including antibody-drug conjugates and cell therapy. New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Positive Sentiment: Gilead also expanded its collaboration with the World Health Organization to help eliminate visceral leishmaniasis, reinforcing its public-health commitment and corporate reputation. Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis
Neutral Sentiment: Several articles highlighted Gilead as a profitable large-cap biotech with strong margins and analyst interest, which may support the stock, but these were largely commentary pieces rather than new fundamental catalysts. Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts
Neutral Sentiment: Gilead launched $3 billion in senior notes, a financing move that is not necessarily negative but may weigh on some investors’ view of leverage and interest expense. Gilead Sciences Launches New $3 Billion Senior Notes
Negative Sentiment: One earnings-call summary pointed to “deal drag,” suggesting some investors may be focused on near-term integration or transaction costs that could temper enthusiasm despite solid overall results. Gilead Sciences Earnings Call Highlights Growth, Deal Drag

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock worth $8,523,570 over the last quarter. 0.30% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.